Cannabinol - 20 mg/ml in methanol
CAS: 521-35-7
Ref. 3D-FC19669
5mg | 136,00 € | ||
10mg | 188,00 € | ||
25mg | 352,00 € | ||
50mg | 548,00 € | ||
100mg | 821,00 € |
Informação sobre produto
- 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol3-Amyl-1-hydroxy-6,6 ,9-trimethyl-6H-dibenzo[b,d]pyran6,6,9-Trimethyl-3-pentyl-6H -dibenzo[b ,d]pyran-1-olCBN
- 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
- 6,6,9-Trimethyl-3-Penyl-6H-Dibenzo(B,D)Puran-1-Ol
- 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
- 6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol
- 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl-
- Cannabinol
- NSC 134455
- cannabinol crystalline--dea*schedule I item
Cannabinol is a moderately psychoactive phytocannabinoid that acts as a partial agonist at the CB1 and the CB2 receptors, preferentially binding to the latter (Ki = 1130 nM and 301 nM, respectively) (Yea, 2000). In vitro binding to the CB2 receptor was demonstrated to trigger apoptotic pathways, blocking the release of cytokines in murine T lymphocytes (Munson, 1975). In vivo animal experimental models showed reduction in primary tumor size and an increase in mean survival time upon treatment with cannabinol in Lewis lung adenocarcinoma (Munson, 1975). Cannabinol was also shown to activate peripheral neuronal receptors and promote vasorelaxation, unlike other synthetic cannabinoid receptor agonists, via a CB receptor-independent mechanism.
Propriedades químicas
Consulta técnica sobre: 3D-FC19669 Cannabinol - 20 mg/ml in methanol
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.